Owing to its prevalence in prostate cancer (293 of 810 samples (36.2%)), ERG was the most frequent fusion driver gene identified in our cohort (295 of 11,091 samples (2.7%)) (Figure 4A). Here, ERG is linked to prostate carcinoma.